neupogen novum 0,6 mg/ml injektionsvæske, opløsning i fyldt injektionssprøjte
amgen europe bv - filgrastim - injektionsvæske, opløsning i fyldt injektionssprøjte - 0,6 mg/ml
neupogen novum 0,96 mg/ml injektionsvæske, opløsning i fyldt injektionssprøjte
amgen europe bv - filgrastim - injektionsvæske, opløsning i fyldt injektionssprøjte - 0,96 mg/ml
accurate delta vanddispergerbart granulat
fmc agricultural solutions a/s (tidligere: cheminova a/s) - diflufenican, metsulfuron-methyl, metsulfuron - vanddispergerbart granulat - 600 g/kg diflufenican ; 60 g/kg metsulfuron-methyl ; (~ 57,8 g/kg metsulfuron
lodin 200 ec flydende middel
agrichem b. v. - fluroxypyr - flydende middel - 200 g/l fluroxypyr
stomp suspensionskoncentrat
basf a/s - pendimethalin - suspensionskoncentrat - 400 g/l pendimethalin
plenum 50 wg vanddispergerbart granulat
syngenta nordics a/s - pymetrozin - vanddispergerbart granulat - 500 g/kg pymetrozin
armure emulsionskoncentrat
syngenta nordics a/s - difenoconazol, propiconazol - emulsionskoncentrat - 150 g/l difenoconazol ; 150 g/l propiconazol
azacitidine celgene
celgene europe bv - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiske midler - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.
quofenix
a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumine - ef-erhvervede infektioner - antibakterielle midler til systemisk brug, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 og 5. det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler..
azacitidine mylan
mylan ireland limited - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiske midler - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.